雷珠单抗治疗不同疾病所致黄斑水肿的疗效观察 Clinical observation of Ranibizumab for macular edema caused by various diseases

Dou Kou, Xiao-Lin Hao, Zhong-Chen Zhang, Zhong -Chen Zhang
unpublished
誗 AIM: To identify the effective and safety of ranibizumab intravitreal injection in patients with macular edema (ME) caused by diabetic macular (DM) and retinal vein obstruction (RVO). 誗METHODS: Thirty-eight eyes of thirty-five patients was retrospectively evaluated, twenty-three with ME caused by DM and fifteen with RVO, who received intravitreal ranibizumab (0. 5mg / 0. 05ml) and were followed up for at least a month. , The best corrected visual acuity (BCVA) , central retinal thickness
more » ... inal thickness (CRT) and intraocular pressure(IOP) were followed up at 1, 3d, 1wk and 1mo respectively. The effect of the DME and RVO-ME were compared. 誗RESULTS: DME and RVO-ME group after treatment in 1, 3d, 1wk, the BCVA were obviously improved, and the differences were statistically significant (P < 0. 05). But compared the BCVA in 1mo with before showed no statistically significant difference (P > 0. 05). DME and RVO-ME group after treatment in 1, 3d, 1wk and 1mo, CRT was obviously improved, and the differences were statistically significant (P < 0. 05). The BCVA and CRT of treatment showed no statistically significant difference between DME with RVO-ME (P>0. 05). 誗 CONCLUSION: Bevacizumab intravitreal injection for ME caused by DM and RVO was safe and effective. 誗 KEYWORDS: ranibizumab; diabetic macular edema; retinal vein obstruction Citation: Kou D, Hao XL, Zhang ZC. Clinical observation of Ranibizumab for macular edema caused by various diseases. Guoji Yanke Zazhi(Int Eye Sci) 2016;16(12) :2272-2275 摘要 目的:探讨玻璃体腔注射雷珠单抗治疗因糖尿病、视网膜 静脉阻塞继发黄斑水肿的安全及有效性。 方法:选取 2013-06 / 2016-02 在北京航天中心医院眼科 因糖尿病继发黄斑水肿(DME) 和视网膜静脉阻塞继发 黄斑水肿(RVO-ME) 收治入院,并符合本研究纳入及排 除标准的患者 35 例 38 眼,其中 DME 23 眼,RVO-ME 15 眼。 患眼接受玻璃体腔雷珠单抗(0. 5mg / 0. 05mL) 注射 治疗,治疗前和治疗后 1、3d,1wk、1mo 定期门诊回访观察 最佳矫正视力(BCVA) 、黄斑中心凹厚度(CRT) 、眼压。 比较雷珠单抗治疗 DME 及 RVO-ME 前后的疗效。 结果:DME 组及 RVO-ME 组治疗后 1、3d,1wk 的 BCVA 均较治疗前提高,差异均有统计学意义(P <0. 05) ,而两 组 1mo 的 BCVA 与治疗前相比差异均无统计学意义(P> 0. 05) 。 DME 组及 RVO-ME 组治疗后 1、3d,1wk,1mo 的 CRT 均较治 疗 前 明 显 改 善, 差 异 均 有 统 计 学 意 义 (P < 0郾 05) 。 在 BCVA 及 CRT 方面比较,雷珠单抗对于 RVO-ME 及 DME 疗效差异无统计学意义(P >0. 05) 。
fatcat:ykwa6ft4mnhnpbxnbso3whq2bq